

Lipid Metabolism Panel

Research for Dyslipidemia and Arteriosclerosis

Pacific Biomarkers
The Value of Expertise



The Lipid Metabolism Panel, developed by IBL and validated by Pacific Biomarkers, can be utilized for monitoring lipid metabolism effects in clinical trials targeting, among others, apoCIII, ANGPTL, and apo(a).

Lipid Metabolism Panel Validation Parameters

Biomarker	Sample Type	Assay Type	Precision		Sensitivity		Relative Reference Interval
			Intra-Assay	Inter-Assay	LLOQ	ULOQ	(mean ± 2SD)
LPL & HTGL Activity (U/L)	Post-heparin Plasma*	Colorimetric	≤ 4.5%	≤ 7.4%	LPL: 11 HTGL: 17	LPL: 153 HTGL: 431	LPL: 42 – 209 HTGL: 198 – 859 (n=20)
HTGL Mass (ng/mL)	Pre-Heparin & Post-Heparin Plasma	ELISA	≤ 4.6%	≤ 9.3%	39.0	2500.0	Pre-Heparin: 16.4 – 108.9 Post-Heparin: 175.9 – 4476.5 (n=16)
EL Mass (ng/mL)	Serum	ELISA	≤ 2.4%	≤ 6.4%	25.0	1600.0	40.6 – 140.6 (n=24)
ANGPTL4 (pg/mL)	Serum	ELISA	≤ 7.6	≤ 12.3%	12.59	1500.00	27.74 – 321.46 (n=20)

* Post-heparin plasma: Blood samples are collected after administration of an intravenous injection of heparin.

AACC Poster Presentation

Performance Evaluation of an Automated Assay for the Measurement of LPL and HL Activity

Number: **B-158**
8/1/2018
12:30 – 1:30 PM